Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 14/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2050779 | 0.93 | CYP3A4 (0.62) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2048826 | 0.93 | PDGFRB (0.56) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL3429470 | 0.93 | CYP3A4 (0.52) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2049244 | 0.88 | CYP3A4 (0.59) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL5132753 | 0.87 | PDGFRB (0.54) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2052671 | 0.86 | PDGFRB (0.61) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL3427296 | 0.86 | PDGFRB (0.62) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL3429960 | 0.86 | CYP3A4 (0.58) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2049256 | 0.85 | CYP3A4 (0.57) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2049957 | 0.84 | PDGFRB (0.57) | CYP3A4PDGFRBCSF1RKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4709139-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | claimed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | claimed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | claimed |
| JP-2006523660-A | — | — | 2006-10-19 | — | — | JP | claimed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | claimed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | claimed |
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | CYP3A4 624/4885PDGFRB 1544/4885CSF1R 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.